[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"claudication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:claudication":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,60,90,120,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100493994","the-effects-of-a-novel-non-ischemic-and-pain-free-exercise-intervention-in-peripheral-artery-disease-100493994",false,"NCT05712395","The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease","NICE","Inclusion Criteria:\n\n1. history of claudication assessed by the Walking Impairment Questionnaire,\n2. ambulatory leg pain in either one or both legs consistent with intermittent claudication confirmed during a screening graded treadmill test using the Gardner-Skinner protocol,\n3. an ABI \\\u003C= 0.90 at rest or \\> 20% decrease in ankle systolic blood pressure in either one or both legs immediately following the treadmill exercise test.\n4. age \\>= 40 years.\n\nExclusion Criteria:\n\n1. absence of PAD (ABI \\> 0.90 at rest and ankle systolic blood pressure \\\u003C 20% decrease after exercise,\n2. inability to obtain an ABI measure due to non-compressible vessels (ABI \\> 1.40),\n3. asymptomatic PAD (Fontaine Stage I) determined from the medical history and verified during the graded treadmill test,\n4. rest pain due to PAD (Fontaine stage III)\n5. tissue loss due to PAD (Fontaine stage IV)\n6. use of medications indicated for the treatment of intermittent claudication (cilostazol and pentoxifylline) initiated within three months prior to investigation,\n7. peripheral revascularization within one month prior to investigation, or peripheral revascularization performed during the study,\n8. exercise tolerance limited by any disease process other than PAD,\n9. active cancer,\n10. kidney failure defined as stage 5 chronic kidney disease,\n11. a calf skin fold measurement \\> 25 mm, because of potential interference with the light path of the NIRS probe from penetrating the subcutaneous tissue,\n12. pulse arterial oxygen saturation of the index finger \\\u003C 95% because of potential deleterious effect on calf muscle StO2 from poor pulmonary gas exchange, and\n13. failure to complete the baseline run-in phase within three weeks.","ALL","40 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a 3-month, prospective, randomized controlled clinical trial designed to address the efficacy of the Non-Ischemic Exercise (NICE) program to improve exercise and vascular outcome measures in patients with peripheral artery disease (PAD).",[26,27],"Claudication","Peripheral Artery Disease","RECRUITING","2026-05-26",{"date":31,"type":32},"2026-05-29","ACTUAL",{"date":34,"type":32},"2024-09-09",{"date":36,"type":20},"2029-07-31",{"name":38,"class":39},"University of Oklahoma","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":40},"100350609","the-effects-of-diet-and-exercise-interventions-in-peripheral-artery-disease-100350609","NCT03845036","The Effects of Diet and Exercise Interventions in Peripheral Artery Disease","Inclusion Criteria:\n\n1. History of claudication,\n2. Presence of PAD, defined by meeting at least one of the following criteria (ABI at rest \\\u003C 0.90, or \\> 20% decrease in ABI following a heel-rise exercise test in patients with a normal ABI at rest (\\> 0.90), or history of peripheral revascularization.\n\nExclusion Criteria:\n\n1. absence of PAD, defined by meeting all of the following 3 criteria (ABI at rest \\> 0.90), \\\u003C 20% decrease in ABI following a heel-rise exercise test, and no history of peripheral revascularization,\n2. non-compressible vessels (ABI \\> 1.40),\n3. rest pain due to PAD (Fontaine stage III; Rutherford Grade II),\n4. tissue loss due to PAD (Fontaine stage IV; Rutherford Grade III),\n5. use of medications indicated for the treatment of intermittent claudication (cilostazol and pentoxifylline) initiated within three months prior to investigation,\n6. peripheral revascularization within one month prior to investigation,\n7. active cancer,\n8. end stage renal disease defined as stage 5 chronic kidney disease,\n9. medical conditions that are contraindicative for exercise according to the American College of Sports Medicine,\n10. cognitive dysfunction (mini-mental state examination score \\\u003C 24), and\n11. failure to complete the baseline tests within three weeks.",{"count":48,"type":20},150,[23],"This study is a 3-month, prospective, randomized controlled clinical trial designed to address the efficacy of the DASH dietary program combined with a home-based exercise program, quantified by a step activity monitor, to improve exercise and vascular outcome measures in patients with PAD.",[26,27],"2026-04-13",{"date":54,"type":32},"2026-04-17",{"date":56,"type":32},"2024-09-16",{"date":58,"type":20},"2029-05-31",{"name":38,"class":39},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":73,"conditions":74,"keywords":79,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100546811","phase-2-fisetin-to-reduce-senescence-and-mobility-impairment-in-pad-100546811","NCT06399809","Fisetin to Reduce Senescence and Mobility Impairment in PAD","Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial","FIRST","Inclusion Criteria:\n\nFirst, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:\n\n1. An ankle brachial index (ABI) less than or equal to 0.90 at baseline.\n2. Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.\n3. An ABI of greater than 0.90 and less than or equal to 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test will also be included.\n\nExclusion Criteria:\n\n1. Above- or below-knee amputation\n2. Critical limb ischemia defined as an ABI less than 0.40 with signs or symptoms of critical limb ischemia\n3. Wheelchair confinement or requiring a walker to ambulate\n4. Walking is limited by a symptom other than PAD\n5. Current foot ulcer on bottom of foot\n6. Failure to successfully complete the study run-in\n7. Planned major surgery, coronary or leg revascularization during the next five months\n8. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months\n9. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. \\[NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.\\]\n10. Mini-Mental Status Examination (MMSE) score less than 23\n11. Allergy to fisetin\n12. Currently taking fisetin or has taken fisetin in previous three months\n13. Non-English speaking\n14. Current participation in or completion of a clinical trial intervention in the previous three months. \\[NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a clinical trial (other than stem cell or gene therapy), participants will be eligible after the final study intervention as long as at least three months have passed since the final intervention of the trial.\\]\n15. Visual impairment that limits walking ability.\n16. Six-minute walk distance of less than 500 feet or greater than1600 feet.\n17. Participation in a supervised treadmill exercise program in previous three months.\n18. Participants may be excluded if they are unwilling to undergo a fat biopsy. However, if investigators find recruitment significantly slows due to this exclusion, participants may still be able to participate in the trial if they refuse the fat biopsy.\n19. Women who are not menopausal will be excluded. Menopause is defined as absence of a menstrual period in the past 12 months.\n20. People with a bilirubin above 2.2 mg\u002Fdl, with serum aspartate transaminase (AST) or alanine aminotransferase (ALT) more than four times the upper limit of normal.\n21. Hemoglobin less than 7.0 g\u002Fdl, white blood count less than 2,000\u002Fmm3, white blood count greater than 20,000\u002Fmm3, platelet count less than 40,000\u002FuL.\n22. Estimated glomerular filtration rate (eGFR) less than 25 ml\u002Fmin\u002F1.73 m2\n23. HemoglobinA1C great than 10 as a marker of poor diabetes control.\n24. People who are Human Immunodeficiency Virus positive (HIV+) and people with active hepatitis B or active hepatitis C infections who do not have a low viral load.\n25. People taking warfarin and other sensitive substrates of CYP2C9, CYP2C19, or CYP1A2 that have a narrow therapeutic window will be excluded, unless the drug can be held for at least two days prior to the first day of each study drug administration and can continue to be held for ten hours after the second dose of study drug administration for each of the two days of study drug dosing.\n26. Body mass index (BMI) great than 43.\n27. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant. In some instances, patients whose medications or laboratory data meet exclusion criteria may participate at the Principal Investigator's discretion.","50 Years",{"count":70,"type":20},34,[72],"PHASE2","The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and\u002For blood.",[75,76,77,78,26],"Peripheral Arterial Disease","Aging","Peripheral Vascular Diseases","Walking, Difficulty",[80],"Fisetin","2026-04-11",{"date":83,"type":32},"2026-04-15",{"date":85,"type":32},"2024-09-30",{"date":87,"type":20},"2027-06",{"name":89,"class":39},"Northwestern University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":100,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":108,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":40},"100610916","presence-of-dural-pulsation-in-patients-diagnosed-with-lumbar-spinal-stenosis-100610916","NCT07233798","Presence of Dural Pulsation in Patients Diagnosed With Lumbar Spinal Stenosis","Correlation of the Presence of Dural Pulsation With Clinical and Radiological Parameters in Patients Diagnosed With Lumbar Spinal Stenosis","Inclusion criteria\n\n* Aged between 18 and 85 years\n* Patients experiencing low back and\u002For leg pain attributable to lumbar spinal stenosis\n* Presence of lumbar spinal stenosis at least at one level consistent with clinical symptoms on lumbar MRI\n* Willingness to participate in the study Exclusion criteria\n* Body Mass Index (BMI) ≥ 35 kg\u002Fm²\n* Patients with radiculopathy due to lumbar disc herniation\n* Patients with axial low back pain caused by facet syndrome, sacroiliac dysfunction, or discogenic pain\n* History of lumbar spine surgery\n* Individuals with mental retardation\n* Patients with major psychiatric comorbidities\n* Patients with congenital spinal anomalies\n* Inflammatory rheumatic diseases characterized by osteophyte formation and ligament calcification, such as ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis (DISH)\n* Pregnancy\n* Patients with heart failure","18 Years","85 Years",{"count":19,"type":20},"1 Year","OBSERVATIONAL","Lumbar spinal stenosis is defined as the narrowing of the spinal canal resulting from degenerative changes in the spinal joints, intervertebral discs, and the ligamentum flavum.\n\nPressure fluctuations within the cerebral and spinal vascular systems lead to the formation of pulsations. The periodic occurrence of these pulsations in the dura mater is referred to as spinal dural pulsation.The vibratory movements of the dura mater have been interpreted as an indicator that the spinal cord is freely mobile within the subarachnoid space and not subjected to any external compression.This study aims to investigate whether the presence of dural pulsation is associated with clinical and radiological parameters in patients diagnosed with lumbar spinal stenosis",[104,105,106,107,26],"Lumbar Spinal Stenosis","Numerical Rating Scale","Disability Physical","Magnetic Resonance",[109,110],"Dural Pulsation","oswestry disability index","2026-03-09",{"date":113,"type":32},"2026-03-11",{"date":115,"type":32},"2025-12-07",{"date":117,"type":20},"2026-12-30",{"name":119,"class":39},"Marmara University",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":40},"100395860","contribution-of-optical-coherence-tomography-in-the-endovascular-treatment-of-femoral-occlusions-100395860","NCT04434586","Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions","TOCAF","Inclusion Criteria:\n\n* Patient over 18 years old\n* Femoral-popliteal lesion TASC-C or TASC-D de novo (F1 to P1)\n* Starting lesion on the superficial femoral artery and not extending beyond the intercondylar notch (P2)\n* ≥1 continuous permeable leg axis directly injecting the plantar arch\n* Rutherford 2-5\n\nExclusion Criteria:\n\n* Patient under personal protection regime (tutorship, guardianship)\n* Absence of arterial axis in permeable leg\n* Patient presenting a limb acute ischaemia (chart evolving since less than 14 days)\n* Patient without favorable element to consider healing\n* History of stents on the femoropopliteal axis\n* History of femoropopliteal bypass\n* Untreated stenosis ≥30% on the iliac axis and common femoral upstream\n* Popliteal lesion beyond the intercondylar notch (P2)",{"count":128,"type":20},166,[23],"This is a common care study. A study for evaluating the quality of balloon inflation and stent application will be performed in 2D angiography alone in the control group and then by 2D and OCT angiography for the experimental group. The benefit could be an improvement in the results of revascularization of femoropopliteal lesions thanks to OCT which allows a 3D visualization of the arterial lumen.",[132,26,133],"Superficial Femoral Artery Stenosis","Ischemic Leg",[135,136,137,138,139],"femoral recanalization","optical coherence tomography (OCT)","endovascular treatment","TASC-C,","TASC-D","2025-12-16",{"date":142,"type":32},"2025-12-23",{"date":144,"type":32},"2020-06-16",{"date":146,"type":20},"2026-06",{"name":148,"class":39},"University Hospital, Lille",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100450437","crush-pad-real-world-outcomes-following-use-of-shockwave-intravascular-lithotripsy-ivl-technology-in-calcified-common-femoral-lesions-100450437","NCT05145478","CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions","CTA_IIT_CRUSH PAD: Real-world Outcomes Following Use of the Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions","Inclusion Criteria:\n\n* Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limbs\n* Subject is a suitable candidate for angiography and endovascular intervention per the latest clinical guidelines\n* Patient is scheduled to undergo treatment with Shockwave Intravascular Lithotripsy (IVL) technology followed by standard of care treatment with DCB, BMS, DES at the physician's discretion.\n\nAngiographic Inclusion Criteria\n\n* Target lesion that is located in a native, de novo common femoral artery\n* Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate.\n* Target lesion is ≥70% stenosis by investigator via visual estimate.\n* Target lesion length is ≤50mm for lesions 70-99% stenosed. Target lesion can be all or part of the 50mm treated zone.\n* Chronic total occlusion, lesion length is ≤50mm of the total ≤50 mm target lesion.\n* Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending \\> 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is \\\u003C50mm in length.\n\nExclusion Criteria:\n\n* Subjects with any medical condition that would make him\u002Fher an inappropriate candidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as per Instructions for Use (IFU) or investigator's opinion.\n* Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints.\n* Cognitive impairment as documented in medical records\n* Not speaking English or Spanish\n* Currently a prisoner\n* Pregnancy or nursing\n* Estimated survival less than 12 months at the time of screening\n* Prior history of CFA endarterectomy",{"count":157,"type":20},50,"The primary goal of the study is to obtain effect size data on the use of Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with peripheral artery disease for a series of endpoints, including target lesion revascularization and health status, to enable future planning of comparative effectiveness research.",[160,75,26,161],"Femoral Arterial Calcification","Critical Limb Ischemia",[27],"2025-11-03",{"date":165,"type":32},"2025-11-05",{"date":167,"type":32},"2021-12-01",{"date":169,"type":20},"2027-06-01",{"name":171,"class":39},"Yale University",2]